Using magnetic stimulation to help people quit smoking
A Pragmatic Feasibility Trial on the Implementation of Transcranial Magnetic Stimulation for Smoking Cessation
This study is testing if a new type of brain stimulation can help daily smokers quit smoking by making it easier for them to stop.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Centre for Addiction and Mental Health Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06346028 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a non-invasive treatment to assist daily smokers in quitting. Participants will undergo a treatment course consisting of daily rTMS sessions for three weeks, followed by weekly sessions for an additional three weeks. The study aims to assess the feasibility of implementing rTMS in the Nicotine Dependence Clinic at the Center for Addiction and Mental Health in Toronto, Canada, while also gathering participant feedback through surveys and interviews.
Who should consider this trial
Good fit: Ideal candidates for this study are daily smokers who are seeking assistance to quit smoking.
Not a fit: Patients with certain medical conditions, such as a history of seizures or those with intracranial implants, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for individuals struggling to quit smoking.
How similar studies have performed: Previous studies have shown success with rTMS for smoking cessation, indicating a promising approach to treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients receiving rTMS * Smoking cigarettes daily (self-reported) Inclusion Criteria: Health care providers * Currently employed as a HCP (physician, social worker, occupational therapist, etc.) at the CAMH NDC * Involved in the care of at least 1 patient who has received rTMS for smoking cessation Exclusion Criteria: Patients receiving rTMS * Have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. * Pregnant or intending to be pregnant during the study. * A history of a primary seizure disorder, seizure associated with an intracranial lesion, recurrent seizures related to substance intoxication or withdrawal or recent seizure within the last 6 months. * Taking any anticonvulsant medication unless it cannot be tapered or discontinued due to risk of clinical safety or destabilization, according to the participant or their referring physician. * Taking benzodiazepines with dose equivalent or greater than lorazepam 2mg/day unless it cannot be tapered or discontinued due to risk of clinical safety or destabilization, according to the participant or their referring physician. * Space occupying intracranial lesion. * Acutely unstable medical, psychiatric, or substance use disorder comorbidity with safety concerns at the discretion of the PI or study physician. Exclusion Criteria: Health care providers \- There are no exclusion criteria for HCP Participants
Where this trial is running
Toronto, Ontario
- Center for Addiction and Mental Health (CAMH) — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Victor Tang, MD, MSc — Center for Addiction and Mental Health
- Study coordinator: Alexandra S, BScH
- Email: rtms.smoking@camh.ca
- Phone: 416-535-8501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.